Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 16/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.38 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296012 | 0.91 | MMP13 (0.49) | MMP13PDE5AGHSRHSD17B13 | |
| SCHEMBL6296055 | 0.90 | MMP13 (0.52) | MMP13PDE5AHSD17B13 | |
| SCHEMBL6302439 | 0.90 | MMP13 (0.52) | MMP13GHSRHSD17B13SLC22A8 | |
| SCHEMBL6297365 | 0.89 | MMP13 (0.51) | MMP13GHSRHSD17B13SLC22A8 | |
| SCHEMBL6302425 | 0.89 | MMP13 (0.56) | MMP13HSD17B13 | |
| SCHEMBL6297383 | 0.89 | MMP13 (0.51) | MMP13GHSRHSD17B13SLC22A8 | |
| SCHEMBL6297484 | 0.87 | MMP13 (0.58) | MMP13EIF4EBP1SLC22A8 | |
| SCHEMBL6296093 | 0.86 | MMP13 (0.49) | MMP13HSD17B13 | |
| SCHEMBL6296209 | 0.86 | MMP13 (0.67) | MMP13PDE5AGHSRHSD17B13 | |
| SCHEMBL6302507 | 0.86 | MMP13 (0.67) | MMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894057-B2 | Oxo-azabicyclic compounds | WARNER-LAMBERT COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-6747147-B2 | INHIBITORS OF TYPE-13 MATRIX METTALOPROTEASE. RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS, AS WELL AS CERTAIN PROLIFERATIVE CONDITIONS SUCH AS CANCERS, PARTICULARLY HUMAN BREAST CANCER | WARNER-LAMBERT COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216402-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, XDH | MMP13 1/4885PDE5A 3282/4885GHSR 1934/4885 |
| US-20030220355-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, CA13 | MMP13 1/4885PDE5A 3137/4885GHSR 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.